Which beta blockers are classified as cardioselective?

Cardioselective beta blockers are those that primarily block beta-1 adrenergic receptors, which are primarily found in the heart. This selectivity helps to reduce heart rate and decrease myocardial contractility, making them particularly effective in treating conditions such as hypertension and heart failure with fewer side effects related to other adrenergic receptors.

Atenolol and Metoprolol are both classified as cardioselective beta blockers. Atenolol has a strong preference for beta-1 receptors, making it effective for various cardiovascular conditions while minimizing effects on beta-2 receptors, which can lead to bronchoconstriction. Metoprolol also exhibits a similar profile, allowing it to reduce heart rate and manage blood pressure effectively without significantly influencing airway resistance.

Propranolol, Timolol, Bisoprolol, Carvedilol, and Sotalol do not share this same level of selectivity. Propranolol and Timolol are non-selective beta blockers, impacting both beta-1 and beta-2 receptors and potentially causing bronchoconstriction and other systemic effects. Bisoprolol is cardioselective but is not included with Atenolol in the correct response. Carvedilol is another non-selective